All companies
Visit website
Throne Biotechnologies
OperatingThrone Biotechnologies Inc.
Healthcare · Biotech · Founded 2011
Find a cure type 1 diabetes, alopecia areata, and other autoimmune disease
Post-money valuation ⓘ
$120.2M
As of May 2022 · from Throne Biotechnologies Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$199,468
Across 1 round since 2022
Latest share price
$7.59
Throne Biotechnologies Common Stock 1 offering price
Financials
FY2019–FY2020 · from SEC filings · hover any figure for its source$0
−$497K
2019
$0
−$482K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$496,520
-$482,168
Taxes paid
$0
$0
Balance sheet
Cash
$208,101
$59,519
Accounts receivable
$0
$0
Total assets
$2,619,727
$2,201,526
Short-term debt
$360,000
$360,000
Long-term debt
$383,699
$409,055
Total liabilities
$743,699
$769,055
Other
Headcount
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$120.2M
post-money
Throne Biotechnologies Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $199.5K / $1MInvestors 102Post-money $120.2M
Reg CF annual-report compliance
Delinquent
Filed 0 of 5 annual reports (FY2021–FY2025)
Missing: 2021, 2022, 2023, 2024, 2025
102 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CFeb 25, 20220001665160-22-000346EDGAR
Source: ManualCIK 0001912674Share price $7.59
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.